

Table A.2.5 (cont.): Overall Results in Male Mice

Organ/tumor	Incidence/p-values									
	Ctrl1	Ctrl2	C1BP3	C1BP4	C1BP5	BP6	BP7	C18	C19	
	pboth	pCvs3	pCvs4	pCvs5	pBP	pCvs6	pCvs7	pC1	pCvs8	pCvs9
HARDERIAN GLAND										
Adenoma	1	0	0	0	1	1	2	1	2	
	.358	.671	.690	.545	.172	.551	.264	.149	.545	.234
Carcinoma	0	0	0	1	0	0	0	0	0	
	.805	.	.310
HEAD										
FIBROMA [B]	0	0	0	0	0	0	0	0	1	
237	.	.315
SCHWANNOMA [M]	0	0	1	0	0	0	0	0	0	
	.618	.329
JEJUNUM										
Adenocarcinoma	0	0	0	0	0	0	0	1	0	
763	.324	.
KIDNEY										
Hemangiosarcoma	1	0	0	0	0	0	0	0	0	
	.415	.671	.690	.680	.503	.676	.662	.516	.676	.685
Tubular Adenoma	0	1	2	0	1	0	0	2	1	
	.444	.252	.690	.539	.503	.676	.662	.344	.246	.532
LIVER										
BASOPHILIC FOCUS (I)	1	2	7	3	4	1	2	3	2	
	.274	.014	.268	.151	.416	.613	.546	.378	.295	.500
CLEAR CELL FOCUS	0	0	2	0	0	1	1	2	1	
	.381	.107	.	.	.189	.324	.338	.184	.104	.315
EOSINOPHILIC FOCUS (I)	1	1	3	0	3	1	3	2	1	
	.160	.200	.474	.187	.134	.695	.213	.620	.391	.682
FOCAL HEPATOCYTE HYPERPLASIA	0	0	0	0	0	0	0	1	0	
764	.329	.
Hemangioma	1	0	1	0	0	0	1	0	0	
	.341	.551	.690	.680	.448	.676	.563	.516	.676	.685
Hemangiosarcoma	1	0	1	1	1	1	1	1	0	
	.324	.548	.523	.542	.393	.542	.560	.523	.542	.687
Hepatocellular Adenoma	12	6	11	11	10	15	19	9	6	
	.460	.342	.259	.453	.010	.069	.008	.225	.529	.301
Hepatocellular Carcinoma	2	6	5	5	6	5	5	2	6	
	.229	.426	.367	.283	.395	.412	.469	.154	.318	.270
LUNG										
Alveolar Bronch. Adenoma	18	8	17	8	12	12	13	11	9	
	.373	.214	.202	.518	.505	.491	.569	.210	.437	.254
Alveolar Bronch. Carcinoma	6	5	8	6	6	5	6	8	9	
	.498	.260	.450	.518	.450	.555	.551	.124	.260	.145
Alveolar Bronch. Hyperplasia	3	3	2	5	3	3	2	6	3	
	.436	.477	.226	.606	.339	.617	.444	.481	.151	.594
Lymph Tissue										
LEUKAEMIA [M]	0	0	0	0	0	0	0	0	1	
237	.	.315
LYMPHOMA [M]	5	3	6	3	9	6	7	4	5	
	.032	.304	.549	.049	.178	.304	.214	.298	.601	.391
Histiocytic Sarcoma	1	3	0	1	1	1	0	1	0	
	.400	.204	.514	.486	.109	.477	.194	.126	.486	.221
MESENTERIC LYMPH NODE										
Hemangioma	0	0	0	0	0	1	0	0	0	
744	.324
Hemangiosarcoma	0	0	1	0	0	0	0	0	0	
	.618	.329

Table A.2.5 (cont.): Overall Results in Male Mice

Organ/tumor	Incidence/p-values									
	Ctrl1	Ctrl2	C1BP3	C1BP4	C1BP5	BP6	BP7	C18	C19	
	pboth	pCvs3	pCvs4	pCvs5	pBP	pCvs6	pCvs7	pC1	pCvs8	pCvs9
PANCREAS										
ISLET CELL ADENOMA [B]	0	1	0	0	0	0	0	0	0	
	.415	.671	.690	.680	.503	.676	.662	.516	.676	.685
Islet Hyperplasia	1	0	1	1	0	1	0	3	2	
	.427	.551	.526	.680	.495	.551	.662	.175	.100	.234
PITUITARY GLAND										
Adenoma	1	2	0	0	3	0	0	0	1	
	.090	.299	.325	.290	.125	.305	.288	.465	.305	.625
Focal Hyperplasia	6	2	2	5	5	4	5	5	4	
	.223	.302	.374	.404	.365	.600	.462	.473	.419	.558
REPRODUCTIVE SYSTEM PENIS										
Fibrosarcoma	0	0	0	0	0	0	1	0	0	
256	.	.338	.	.	.
SALIVARY GLAND										
Carcinoma	0	0	0	0	0	0	0	1	1	
173	.324	.315
SEMINAL VESICLE										
Adenoma	0	0	0	0	0	0	0	1	0	
763	.324	.
SKELETAL MUSCLE										
Hemangiosarcoma	0	1	0	0	0	0	0	0	0	
	.415	.671	.690	.680	.503	.676	.662	.516	.676	.685
SKIN AND SUBCUTIS										
PAPILLOMA [B]	0	0	0	0	0	0	2	0	0	
065	.	.113	.	.	.
SQUAMOUS-CELL CARCINOMA [M]	0	0	0	0	0	0	0	0	1	
237	.	.315
Basal Cell Tmr	0	0	1	0	0	0	1	0	1	
	.618	.329	.	.	.256	.	.338	.241	.	.320
Fibrosarcoma	0	0	0	0	0	0	1	1	0	
256	.	.338	.763	.324	.
Fibrous Histiocytoma	0	0	0	0	1	0	1	1	0	
	.198	.	.	.324	.256	.	.338	.763	.324	.
Sarcoma	1	1	0	0	0	0	1	0	0	
	.173	.452	.477	.464	.589	.458	.739	.267	.458	.471
SPLEEN										
Hemangiosarcoma	0	1	0	1	1	0	0	0	0	
	.260	.671	.526	.545	.503	.676	.662	.516	.676	.685
STOMACH										
Basal Cell Tmr	0	0	1	0	0	0	0	0	0	
	.618	.329
Systemic										
Hemangioma	1	0	1	2	0	3	1	0	0	
	.392	.551	.228	.680	.420	.100	.563	.516	.676	.685
Hemangioma/Hemangiosarcoma	3	2	2	4	1	4	3	1	0	
	.247	.591	.280	.374	.445	.314	.535	.073	.374	.151
Hemangiosarcoma	2	2	1	2	1	1	2	1	0	
	.386	.477	.597	.486	.523	.486	.653	.126	.486	.221
TESTIS										
Adenoma	0	0	0	2	0	0	0	1	0	
	.647	.	.095763	.324	.
Hemangioma	0	0	0	1	0	1	0	0	0	
	.805	.	.310	.	.744	.324
Interst. Cell Adenoma	2	3	1	2	5	4	2	3	2	
	.065	.356	.625	.188	.402	.336	.560	.494	.512	.614
Interst. Cell Hyperplasia	1	1	4	2	0	0	1	2	0	
	.139	.091	.366	.461	.591	.455	.736	.302	.391	.468

Table A.2.5 (cont.): Overall Results in Male Mice

Organ/tumor	Incidence/p-values									
	Ctrl1	Ctrl2	C1BP3	C1BP4	C1BP5	BP6	BP7	C18	C19	
	pboth	pCvs3	pCvs4	pCvs5	pBP	pCvs6	pCvs7	pC1	pCvs8	pCvs9
THYROID GLAND										
Follic. Cell Hyperplasia	0	0	1	0	0	0	0	1	0	
	.618	.329763	.324	.

Table A.2.6: Overall Results in Female Mice

Organ/tumor	Incidence/p-values									
	Ctrl1	Ctrl2	C1BP3	C1BP4	C1BP5	BP6	BP7	C18	C19	
	pboth	pCvs3	pCvs4	pCvs5	pBP	pCvs6	pCvs7	pC1	pCvs8	pCvs9
ABDOMEN										
Fibrosarcoma	0	0	0	1	0	0	0	0	0	
	.801	.	.356
Sarcoma	0	0	0	0	0	1	0	0	1	
728	.310	.	.238	.	.320
ADRENAL GLAND										
Medullary Hyperplasia	2	0	1	1	0	0	0	1	1	
	.244	.726	.712	.433	.251	.475	.420	.544	.739	.690
Phaeochromocytoma	0	0	0	0	0	1	0	0	0	
730	.315
Small-Cell Focus	0	0	0	0	0	0	0	1	0	
762	.336	.
BONE										
OSTEOSARCOMA [M]	0	1	0	0	0	0	1	0	0	
	.385	.654	.644	.659	.471	.691	.580	.506	.664	.680
Hemangiosarcoma	0	0	0	0	1	0	0	0	0	
	.199	.	.	.341
Osteoma	1	0	0	0	0	2	0	0	0	
	.385	.654	.644	.659	.375	.233	.649	.506	.664	.680
CAECUM										
Glandular Hyperplasia	0	0	0	0	0	0	0	0	1	
243	.	.326
Leiomyosarcoma	0	0	0	0	0	0	1	0	0	
272	.	.351	.	.	.
CERVIX										
LEIOMYOMA [B]	0	0	1	0	0	0	0	0	0	
	.589	.346
Polyp	1	0	1	0	0	1	0	0	0	
	.305	.574	.644	.659	.480	.525	.649	.506	.664	.680
Stromal Sarcoma	0	1	0	0	0	0	0	0	0	
	.385	.654	.644	.659	.503	.691	.649	.506	.664	.680
DUODENUM										
Glandular Hyperplasia	0	0	2	0	0	0	0	1	0	
	.345	.118762	.336	.
FEMUR										
Hemangiosarcoma	0	0	1	0	0	0	0	0	0	
	.589	.346
HARDERIAN GLAND										
Adenoma	0	0	0	0	0	1	0	0	0	
728	.310
KIDNEY										
Focal Tub. Epi. Hyperplasia	0	1	0	0	0	0	0	0	0	
	.388	.657	.647	.662	.506	.693	.652	.509	.667	.682

Table A.2.6 (cont.): Overall Results in Female Mice

Organ/tumor	Incidence/p-values									
	Ctrl1	Ctrl2	ClBP3	ClBP4	ClBP5	BP6	BP7	Cl8	Cl9	
	pboth	pCvs3	pCvs4	pCvs5	pBP	pCvs6	pCvs7	pCl	pCvs8	pCvs9
LIVER										
BASOPHILIC FOCUS (I)	0	0	1	1	1	0	0	0	0	
	.181	.346	.356	.341
CLEAR CELL FOCUS	0	0	0	0	0	0	1	0	0	
272	.	.351	.	.	.
EOSINOPHILIC FOCUS (I)	0	0	0	0	0	0	0	0	1	
238	.	.320
Hemangioma	0	0	0	0	0	0	1	0	0	
272	.	.351	.	.	.
Hemangiosarcoma	1	2	1	2	0	0	3	0	1	
	.176	.575	.589	.286	.207	.329	.357	.460	.293	.621
Hepatocellular Adenoma	2	2	1	0	2	1	1	1	0	
	.415	.434	.168	.668	.315	.507	.424	.114	.453	.209
Hepatocellular Carcinoma	0	0	0	1	0	0	0	0	0	
	.801	.	.356
LUNG										
Alveolar Bronch. Adenoma	6	8	8	4	6	2	4	6	1	
	.355	.503	.153	.434	.168	.063	.175	.011	.474	.020
Alveolar Bronch. Carcinoma	3	3	3	2	2	3	6	2	5	
	.319	.628	.417	.452	.135	.575	.199	.156	.465	.256
Alveolar Bronch. Hyperplasia	0	2	2	1	1	4	1	0	1	
	.480	.430	.712	.732	.385	.073	.719	.568	.439	.697
Lymph Tissue										
LYMPHOMA [M]	15	10	7	9	9	9	12	11	8	
	.284	.087	.173	.206	.421	.363	.451	.172	.424	.213
Histiocytic Sarcoma	7	2	3	6	4	4	6	6	6	
	.460	.364	.468	.512	.342	.627	.436	.304	.403	.369
MAMMARY GLAND										
Adenoma	0	0	0	0	0	0	0	1	0	
762	.336	.
Alveolar Hyperplasia	0	0	0	1	0	0	0	1	0	
	.801	.	.356762	.336	.
Carcinoma	2	2	1	0	0	0	3	2	0	
	.030	.434	.168	.184	.287	.222	.470	.128	.668	.209
Epithelial Hyperplasia	0	0	0	0	0	0	0	2	0	
579	.111	.
Lobular Hyperplasia	4	1	1	1	1	1	3	0	2	
	.235	.327	.308	.336	.430	.400	.572	.526	.127	.607
MESENTERIC LYMPH NODE										
Hemangioma	0	0	0	0	0	0	1	0	0	
272	.	.351	.	.	.
OVARY										
UNILATERAL CYSTADENOMA [B]	1	2	1	0	2	0	0	1	0	
	.330	.570	.264	.557	.125	.326	.270	.196	.588	.311
UNILATERAL LUTEOMA [B]	0	0	1	0	0	0	0	0	0	
	.589	.346
Fibrosarcoma	0	0	0	0	1	0	0	0	0	
	.203	.	.	.346
Gran./Thecal Cell Tmr	1	1	1	1	0	1	0	0	1	
	.247	.729	.716	.436	.299	.679	.423	.558	.443	.686
Tubular Adenoma	0	1	0	0	0	0	0	0	0	
	.385	.654	.644	.659	.503	.691	.649	.506	.664	.680
PANCREAS										
ISLET CELL ADENOMA [B]	0	0	0	0	1	1	1	2	1	
	.199	.	.	.341	.196	.310	.351	.188	.111	.320
Islet Hyperplasia	0	0	1	1	1	0	1	1	0	
	.181	.346	.356	.341	.272	.	.351	.762	.336	.

Table A.2.6: Overall Results in Female Mice

Organ/tumor	Incidence/p-values									
	Ctrl1	Ctrl2	C1BP3	C1BP4	C1BP5	BP6	BP7	C18	C19	
	pboth	pCvs3	pCvs4	pCvs5	pBP	pCvs6	pCvs7	pC1	pCvs8	pCvs9
PARATHYROID GLAND										
Focal Hyperplasia	0	0	0	0	0	0	0	0	1	
238	.	.320
PITUITARY GLAND										
Adenoma	2	1	1	1	2	2	1	0	1	
	.347	.570	.553	.557	.423	.493	.561	.456	.290	.616
Carcinoma	0	0	0	0	0	0	0	1	0	
763	.341	.
Focal Hyperplasia	0	1	4	2	1	0	1	2	0	
	.447	.048	.288	.567	.471	.691	.580	.424	.261	.680
SALIVARY GLAND										
Carcinoma	0	0	0	0	0	0	1	0	0	
272	.	.351	.	.	.
SKIN AND SUBCUTIS										
KERATOACANTHOMA [B]	0	0	0	0	0	0	1	0	0	
272	.	.351	.	.	.
PAPILLOMA [B]	0	0	0	0	1	0	1	0	0	
	.199	.	.	.341	.272	.	.351	.	.	.
RHABDOMYOSARCOMA [M]	0	0	0	1	0	0	0	0	0	
	.801	.	.356
Basal Cell Tmr	0	0	0	0	0	1	0	0	0	
730	.315
Fibrosarcoma	1	0	0	0	0	0	0	1	2	
	.385	.654	.644	.659	.503	.691	.649	.154	.561	.240
Fibrous Histiocytoma	0	0	0	0	1	0	0	0	0	
	.199	.	.	.341
Sarcoma	1	1	1	0	0	0	1	0	0	
	.147	.726	.414	.433	.616	.475	.719	.254	.439	.460
SPLEEN										
Hemangiosarcoma	0	0	0	1	0	1	1	1	0	
	.801	.	.356	.	.196	.310	.351	.762	.336	.
STOMACH										
SQUAMOUS-CELL PAPILLOMA [B]	0	0	0	1	0	0	0	0	0	
	.801	.	.356
Systemic										
Hemangioma	0	0	1	2	0	1	2	0	0	
	.504	.346	.128	.	.069	.310	.121	.	.	.
Hemangioma/Hemangiosarcoma	1	2	3	7	2	3	4	2	1	
	.419	.337	.027	.552	.150	.265	.199	.487	.542	.621
Hemangiosarcoma	1	2	2	5	2	2	3	2	1	
	.453	.561	.108	.552	.261	.488	.357	.487	.542	.621
THYROID GLAND										
Follic. Cell Hyperplasia	1	0	1	0	1	1	1	1	0	
	.405	.574	.644	.574	.409	.525	.580	.515	.561	.680
URINARY BLADDER										
Sarcoma	1	0	0	0	0	0	0	0	0	
	.385	.654	.644	.659	.503	.691	.649	.506	.664	.680

b(4)

Table A.2.6: Overall Results in Female Mice

Organ/tumor	Incidence/p-values									
	Ctrl1	Ctrl2	C1BP3	C1BP4	C1BP5	BP6	BP7	C18	C19	
	pboth	pCvs3	pCvs4	pCvs5	pBP	pCvs6	pCvs7	pC1	pCvs8	pCvs9
UTERUS										
LEIOMYOMA [B]	1	1	0	1	0	0	1	1	0	
	.297	.426	.712	.433	.616	.475	.719	.325	.739	.460
Adenocarcinoma	1	0	1	0	1	0	0	0	0	
	.399	.574	.644	.567	.503	.691	.649	.506	.664	.680
Hemangioma	0	0	1	2	0	1	0	0	0	
	.504	.346	.128	.	.728	.310
Hemangiosarcoma	0	0	0	2	1	1	0	1	0	
	.129	.	.125	.341	.728	.310	.	.762	.336	.
Leiomyosarcoma	1	0	1	0	0	1	0	0	0	
	.305	.574	.644	.659	.480	.525	.649	.506	.664	.680
Polyp	5	7	0	6	4	7	5	3	5	
	.436	.005	.539	.310	.282	.374	.401	.504	.182	.532
Stromal Sarcoma	1	1	3	7	1	2	5	0	0	
	.259	.221	.010	.736	.032	.360	.053	.257	.443	.464
VAGINA										
Polyp	0	2	1	1	0	0	1	0	0	
	.245	.729	.709	.436	.614	.478	.722	.257	.443	.464

Appendix 3. Mice Tumor Name Conversions

As noted in Section 2.2 the mouse data set was characterized by long tumor codes and tumor names, as well as very fine subgroupings of the tumors. The two former problems caused difficulties with our software, while the latter problem made it more difficult to detect treatment differences. The table below shows the new tumor name and the original tumor name from the submitted data set.

Table A.3.1 Conversion of Tumor Groups

<u>New Tumor Name</u>	<u>Original Tumor Name</u>
Adenocarcinoma	ADENOCARCINOMA [M] METASTASISING ADENOCARCINOMA [M]
Adenoma	ADENOMA [B] INTERMEDIATE LOBE ADENOMA [B] UNILATERAL ADENOMA [B] UNILATERAL RETE TESTIS ADENOMA [B]
Alveolar Bronch. Adenoma	(ASSOCIATED) ALVEOLAR/BRONCHIOLAR ADENOMA MULTIPLE [B] (ASSOCIATED) ALVEOLAR/BRONCHIOLAR ADENOMA [B] ALVEOLAR/BRONCHIOLAR ADENOMA MULTIPLE [B] ALVEOLAR/BRONCHIOLAR ADENOMA [B]
Alveolar Bronch. Carcinoma	ALVEOLAR/BRONCHIOLAR CARCINOMA MULTIPLE [M] ALVEOLAR/BRONCHIOLAR CARCINOMA [M] METASTASISING ALVEOLAR/BRONCHIOLAR CARCINOMA MULTIPLE [M] METASTASISING ALVEOLAR/BRONCHIOLAR CARCINOMA [M]
Alveolar Bronch. Hyperplasia	(ASSOCIATED) BRONCHIOLAR ALVEOLAR HYPERPLASIA BRONCHIOLAR ALVEOLAR HYPERPLASIA FOCAL (ASSOCIATED) BRONCHIOLAR ALVEOLAR HYPERPLASIA FOCAL BRONCHIOLAR ALVEOLAR HYPERPLASIA
Alveolar Hyperplasia	(ASSOCIATED) ALVEOLAR HYPERPLASIA ALVEOLAR HYPERPLASIA
Basal Cell Tumor	BASAL CELL TUMOUR [B] BASAL CELL TUMOUR [M] METASTASISING BASAL CELL TUMOUR [M]
Carcinoma	CARCINOMA [M] METASTASISING CARCINOMA [M] UNILATERAL CARCINOMA [M]
Epithelial Hyperplasia	EPITHELIAL HYPERPLASIA FOCAL EPITHELIAL HYPERPLASIA
Fibrosarcoma	FIBROSARCOMA MULTIPLE [M] FIBROSARCOMA [M] METASTASISING FIBROSARCOMA [M] UNILATERAL FIBROSARCOMA [M]

Table A.3.1 (cont.) Conversion of Tumor Groups

Fibrous Histiocytoma	FIBROUS HISTIOCYTOMA [B] FIBROUS HISTIOCYTOMA [M]
Focal Hyperplasia	FOCAL (ASSOCIATED) HYPERPLASIA FOCAL HYPERPLASIA FOCAL INTERMEDIATE LOBE HYPERPLASIA UNILATERAL FOCAL HYPERPLASIA
Focal Tub. Epi. Hyperplasia	FOCAL TUBULAR EPITHELIAL HYPERPLASIA
Follic. Cell Hyperplasia	BILATERAL FOLLICULAR-CELL HYPERPLASIA UNILATERAL FOLLICULAR CELL ADENOMA [B] UNILATERAL FOLLICULAR-CELL HYPERPLASIA
Glandular Hyperplasia	FOCAL GLANDULAR HYPERPLASIA LOCALISED GLANDULAR HYPERPLASIA
Gran./Thecal Cell Tmr	METASTASISING UNILATERAL GRANULOSA/THECAL CELL TUMOUR [M] UNILATERAL GRANULOSA/THECAL CELL TUMOUR [B] UNILATERAL GRANULOSA/THECAL CELL TUMOUR [M]
Hemangioma	(ASSOCIATED) HAEMANGIOMA [B] HAEMANGIOMA [B] UNILATERAL HAEMANGIOMA [B]
Hemangiosarcoma	HAEMANGIOSARCOMA MULTIPLE [M] HAEMANGIOSARCOMA [M] METASTASISING HAEMANGIOSARCOMA [M] UNILATERAL HAEMANGIOSARCOMA [M]
Hemangioma/Hemangiosarcoma	(ASSOCIATED) HAEMANGIOMA [B] HAEMANGIOMA [B] HAEMANGIOSARCOMA MULTIPLE [M] HAEMANGIOSARCOMA [M] METASTASISING HAEMANGIOSARCOMA [M] UNILATERAL HAEMANGIOMA [B] UNILATERAL HAEMANGIOSARCOMA [M]
Hemangiosarcoma	HAEMANGIOSARCOMA MULTIPLE [M] HAEMANGIOSARCOMA [M] METASTASISING HAEMANGIOSARCOMA [M] UNILATERAL HAEMANGIOSARCOMA [M]
Hepatocellular Adenoma	(ASSOCIATED) HEPATOCELLULAR ADENOMA MULTIPLE [B] (ASSOCIATED) HEPATOCELLULAR ADENOMA [B] HEPATOCELLULAR ADENOMA MULTIPLE [B] HEPATOCELLULAR ADENOMA [B]
Hepatocellular Carcinoma	HEPATOCELLULAR CARCINOMA MULTIPLE [M] HEPATOCELLULAR CARCINOMA [M] METASTASISING HEPATOCELLULAR CARCINOMA [M]

b(4)

NDA 50819 — — — Gel

Dow Pharmaceuticals, Inc.

Table A.3.1 (cont.) Conversion of Tumor Groups

Histiocytic Sarcoma
AXILLARY INFILTRATION BY HISTIOCYTIC SARCOMA CELLS
BRONCHIAL INFILTRATION BY HISTIOCYTIC SARCOMA CELLS (RELATES TO
ENLARGEME
HEPATIC INFILTRATION BY HISTIOCYTIC SARCOMA CELLS
HEPATIC INFILTRATION BY HISTIOCYTIC SARCOMA CELLS (RELATES TO
ENLARGEMENT
HISTIOCYTIC SARCOMA [M]
LUMBAR INFILTRATION BY HISTIOCYTIC SARCOMA CELLS
LUMBAR INFILTRATION BY HISTIOCYTIC SARCOMA CELLS (RELATES TO DARKENING)
LUMBAR INFILTRATION BY HISTIOCYTIC SARCOMA CELLS (RELATES TO
ENLARGEMENT)
LUMBAR INFILTRATION BY HISTIOCYTIC SARCOMA CELLS (WITH CONGESTION,
RELATE
MEDIASTINAL INFILTRATION BY HISTIOCYTIC SARCOMA CELLS (RELATES TO
ENLARGE
PANCREATIC INFILTRATION BY HISTIOCYTIC SARCOMA CELLS (ACCOUNTS FOR
ENLARG
THYMIC INFILTRATION BY HISTIOCYTIC SARCOMA CELLS
Interst. Cell Adenoma
BILATERAL INTERSTITIAL CELL ADENOMA [B]
UNILATERAL INTERSTITIAL CELL ADENOMA [B]
Interst. Cell Hyperplasia
BILATERAL FOCAL INTERSTITIAL CELL HYPERPLASIA
FOCAL INTERSTITIAL CELL HYPERPLASIA
UNILATERAL (ASSOCIATED) FOCAL INTERSTITIAL CELL HYPERPLASIA
UNILATERAL FOCAL INTERSTITIAL CELL HYPERPLASIA
Islet Hyperplasia
FOCAL ISLET CELL HYPERPLASIA
ISLET CELL HYPERPLASIA
Leiomyosarcoma
LEIOMYOSARCOMA [M]
METASTASISING LEIOMYOSARCOMA [M]
Lobular Hyperplasia
(ASSOCIATED) LOBULAR HYPERPLASIA
LOBULAR HYPERPLASIA
Medullary Hyperplasia
FOCAL UNILATERAL MEDULLARY HYPERPLASIA
UNILATERAL MEDULLARY HYPERPLASIA
Osteoma
OSTEOMA MULTIPLE [B]
OSTEOMA [B]
Pheochromocytoma
BILATERAL PHAEOCHROMOCYTOMA [M]
UNILATERAL PHAEOCHROMOCYTOMA [B]
UNILATERAL PHAEOCHROMOCYTOMA [M]
Polyp
(ASSOCIATED) POLYP [B]
POLYP MULTIPLE [B]
POLYP [B]
Sarcoma
METASTASISING SARCOMA [M]
SARCOMA [M]

Table A.3.1 (cont.) Conversion of Tumor Groups

Small-Cell Focus

BILATERAL CORTICAL SMALL-CELL FOCUS (I)
 CORTICAL SMALL-CELL FOCUS (I)
 UNILATERAL CORTICAL SMALL-CELL FOCUS (I)

Stromal Sarcoma

METASTASISING STROMAL SARCOMA [M]
 STROMAL SARCOMA [M]

Tubular Adenoma

BILATERAL TUBULAR ADENOMA [B]
 UNILATERAL TUBULAR ADENOMA [B]

Not renamed or pooled:

ASTROCYTOMA [M]	MESOTHELIAL HYPERPLASIA
BASOPHILIC FOCUS (I)	OSTEOSARCOMA [M]
CLEAR CELL FOCUS	PAPILLOMA [B]
EOSINOPHILIC FOCUS (I)	RHABDOMYOSARCOMA [M]
FIBROMA [B]	SCHWANNOMA [M]
FOCAL HEPATOCYTE HYPERPLASIA	SQUAMOUS-CELL CARCINOMA [M]
ISLET CELL ADENOMA [B]	SQUAMOUS-CELL PAPILLOMA [B]
KERATOACANTHOMA [B]	UNILATERAL CORTICAL ADENOMA [B]
LEIOMYOMA [B]	UNILATERAL CYSTADENOMA [B]
LEUKAEMIA [M]	UNILATERAL LUTEOMA [B]
LYMPHOMA [M]	

Appendix 4. References

- Bailer, A. and Portier, C. (1988), "Effects of Treatment-Induced Mortality on Tests for Carcinogenicity in Small Samples", *Biometrics*, **44**, 4, 417-431.
- Bieler, G.S., and Williams, R.L. (1993), "Ratio Estimates, the Delta Method, and Quantal Response Tests for Increased Carcinogenicity", *Biometrics*, **49**, 4, 793-801.
- Chu, K.C., Ceuto, C., and Ward, J.M. (1981), Factors in the Evaluation of 200 National Cancer Institute Carcinogen Bioassays, *Journal of Toxicology and Environmental Health*, **8**, 251-280.
- Haseman, J. K. (1983), A Reexamination of False-positive Rates for Carcinogenicity Studies, *Fundamental and Applied Toxicology*, **3**, 334-339.
- Ibrahim, J.G., Chen, M.-H., and Sinha, D. (2001), *Bayesian Survival Analysis*, Springer Verlag, New York.
- Lin, K. K. and Ali, M.W. (2006), Statistical Review and Evaluation of Animal Tumorigenicity Studies, *Statistics in the Pharmaceutical Industry, Third Edition*, edited by C.R. Buncher and J.Y. Tsay, Marcel Dekker, Inc. New York.
- Lin, K. K. and Rahman, M.A. (1998), Overall False Positive Rates in Tests for Linear Trend in Tumor Incidence in Animal Carcinogenicity Studies of New Drugs, *Journal of Biopharma-ceutical Statistics*, **8**(1), 1-15.
- McConnell, E.E., Solleveld, H.A., Swenberg, J.A., and Boorman, G.A. (1986), Guidelines for Combining Neoplasms for Evaluation of Rodent Carcinogenesis Studies, *Journal of the National Cancer Institute*, **76**, 283-289.
- Peto, R., Pike, M.C., Day, N.E., Gray, R.G., Lee, P.N., Parrish, S., Peto, J., Richards, S., and Wahrendorf, J. (1980). Guidelines for sample sensitive significance tests for carcinogenic effects in long-term animal experiments, *IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, supplement 2: Long term and Short term Screening Assays for Carcinogens: A Critical Appraisal*, International Agency for Research Against Cancer, 311-426.
- STP Peto Working Group (2002), Statistical Methods for Carcinogenicity Studies, *Toxicologic Pathology*, **30** (3), 403-414.
- U.S. Department of Health and Human Services (2001), *Guidance for Industry Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals (DRAFT GUIDANCE)*, Center for Drug Evaluation and Research, Food and Drug Administration.

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Steven Thomson
9/26/2008 08:12:04 AM
BIOMETRICS

Karl Lin
9/26/2008 08:37:57 AM
BIOMETRICS
Concur with review